Clinical Trial

Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives

Study acronym: HEPAGLY
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.
Trial Details
NCT Number NCT07303140
Lead Sponsor University Hospital, Strasbourg, France
Conditions Liver Fibrosis
Enrollment 30 participants
Start Date 2024-10-18
Primary Completion 2026-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-24